Mar
8
2023
On demand
Enabling and advancing mRNA-LNP medicines from concept to clinic
Wednesday 08:00 PST / 11:00 EST / 16:00 GMT / 17:00 CET
Sponsor
Nucleic acids (e.g., siRNA, mRNA, and saRNA) can be designed and formulated to silence, express, and edit specific genes providing a flexible and powerful approach to preventing and treating diseases. The recent commercialization and widespread distribution of COVID-19 mRNA vaccines has exemplified the massive potential to rapidly develop and scale-up new genomic medicines to protect from emerging viral threats and treat a wide range of serious diseases with unmet medical needs.
This webinar will discuss key insights and experiences that leverage modular microfluidic platform technologies and analytics to enable rapid development, testing, and scale-up of mRNA-LNP vaccines and therapeutics:
- Examples from our internal R&D work to demonstrate the versatility of the genetic medicine toolbox for the rapid development of RNA-LNP Vaccines
- Key considerations during development of mRNA-LNP medicines and how a comprehensive understanding of Critical Quality Attributes (CQAs) and Key process parameters are critical in developing mRNA-LNP that meet the target product profile
- Challenges associated with mRNA-LNP analytical development and impact on biological activity
- How Precision NanoSystems employs a panel of over 25 specific assays to de-risk LNP development programs and expedite the path to the clinic
SPEAKERS
You might also like
Same-section spatial multiomics: a platform for detailed analysis of the solid tumor TME
Emily Neil, Ariadna Pascual
27 June
in 69
Days
Pure and simple: understanding LNP analytics for better mRNA-based drugs
Adam Crowe
29 May
in 40
Days
Empowering patient care: in-process and quality control solutions for cellular therapies
Christin Tischner, Simon Lennartz
23 May
in 34
Days
T cells from beginning to end: optimizing leukopak and drug product cryopreservation
Meredith Safford, ShaNelle Yelity
22 May
in 33
Days
Mastering AAV production: best practices For small- to large-scale manufacturing success and reduced development time
Emily Jackson-Holmes
21 May
in 32
Days